Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement

Reuters10-08

<a href="https://laohu8.com/S/ACET">Adicet Bio</a> Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement

**Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233427), on October 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573935319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573935319","market":"us","top_or_hot":-1,"title":"Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a> Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233427), on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 04:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a> Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233427), on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACET","symbol_name":"艾切托","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL8dh3tM:1","article_id":"2573935319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573935319","pubTimestamp":1759867336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACET":"艾切托","BK4139":"生物科技"},"translate_title":"Adicet Bio在未达到最低投标价格要求后获得纳斯达克延期以恢复合规性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACET":0.9},"content_text":"Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement\n    \n\n        **Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233427), on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573935319","isCrawlerRequest":true}